X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
United States Patent and Trademark Office has issued the Company a new Notice of Allowance for a patent on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme important for tumor cell growth, invasion and metastasis.
Lead Product(s): SBI-183
Therapeutic Area: Oncology Product Name: SBI-183
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: AXIM Biotechnologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
The grant will support the continued development of novel small molecules that inhibit the enzymatic activity of Quiescin Sulfhydryl Oxidase I (“QSOX1”) based on a lead compound. QSOX1 is a tumor-derived enzyme that is important for cancer growth, invasion and metastasis.
Lead Product(s): SPX-1009
Therapeutic Area: Oncology Product Name: SPX-1009
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Division of Cancer Treatment and Diagnosis
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding August 11, 2020
Details:
Sapphire scientists have generated and tested over 90 analogs of SBI-183 and discovered that one analog, SPX-1009, was tenfold more potent than SBI-183 in suppressing tumor invasion and metastasis in vitro.
Lead Product(s): SPX-1009
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: AXIM Biotechnologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
SI, the intellectual property management company for Arizona State University, licensed the Patents, Technical Information and Materials to Sapphire on behalf of SI and Mayo Clinic.
Lead Product(s): SBI-183
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Skysong Innovations
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 22, 2020
Details:
AXIM® Biotechnologies, has signed a binding term sheet to acquire leading oncology research and development company Sapphire Biotech as a wholly-owned subsidiary.
Lead Product(s): Cannabinoid-like molecules
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: AXIM Biotechnologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
